Allodynic Therapeutics

Executive Summary

Allodynic Therapeutics is a Boston-based clinical-stage biopharmaceutical company developing a novel fixed-dose combination of naltrexone and acetaminophen for acute migraine, migraine prevention, and neuropathic pain. By leveraging the synergistic effects of two well-established drugs, the company aims to provide effective analgesia through multiple pain pathways while avoiding the addiction risks associated with opioids. Its intellectual property is protected by U.S. patents extending to 2037, providing a competitive moat. The company is privately held and has raised no disclosed funding, operating with a lean approach typical of early-stage biotechs. The company is currently in Phase 2 clinical development for its lead indication, acute migraine. The repurposed drug combination offers a potentially safer alternative to triptans and opioids, with a favorable safety profile given the long history of both components. If successful, Allodynic could address a significant unmet need in migraine and neuropathic pain markets. However, the company faces development risks and competition from established therapies and other pipeline candidates. Upcoming catalysts include Phase 2 data readouts and potential partnership discussions, which will be critical for the company's valuation and path to commercialization.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Topline Results for Acute Migraine40% success
• Q2 2027Phase 2 Initiation or Results for Neuropathic Pain35% success
• H1 2027Partnership or Licensing Agreement30% success